医学
人工智能
疾病
内科学
放射科
支持向量机
慢性肝病
纤维化
外科
领域(数学)
机器学习
肝纤维化
肝硬化
作者
Yuanyuan Chen,Tianbiao Yang,Tianlu Chen,Huanming Xiao,Kejun Zhou,Keke Ding,Quan Liu,Mengci Li,Xufei Peng,Tao Sun,Xiaoning Wang,Ping Liu,Xin Deng,Zheng Zhang,Xinliang Zhang,Xianzhang Huang,Xiaoling Chi,Alice Pik-Shan Kong,V. W.S. Wong,Wei Jia
标识
DOI:10.1016/j.xcrm.2026.102726
摘要
Accurate, non-invasive liver fibrosis detection is essential for chronic liver disease management, particularly with rising metabolic dysfunction-associated liver disease (MASLD) and chronic hepatitis B (CHB). While the Fibrosis-4 (FIB-4) index is widely used, its performance for advanced fibrosis is limited. We develop Met-FIB using metabolomics and machine learning, integrating FIB-4 parameters (age, aspartate aminotransferase, alanine aminotransferase, and platelet count) with tyrosine and taurocholic acid identified in a CHB discovery cohort (n = 3,251). Validation includes one CHB cohort (n = 729) and two MASLD cohorts (n = 149, n = 155). Met-FIB outperforms FIB-4, FibroScan, and other serum markers across all fibrosis stages. In CHB, Met-FIB achieves 96.3% rule-out sensitivity and 85.4% rule-in specificity for significant fibrosis, with rule-in specificity reaching 98.6% and 98.8% for advanced fibrosis and cirrhosis. In MASLD, corresponding values are 93.9% and 90.2% for significant fibrosis, with >97.9% specificity for late-stage disease. Met-FIB demonstrates clinical utility for non-invasive fibrosis staging across diverse etiologies.
科研通智能强力驱动
Strongly Powered by AbleSci AI